AusPAR: Vedolizumab (rch)

Australian Public Assessment Report

AusPAR

AusPAR: Vedolizumab (rch) [PDF, 961.6 KB]

AusPAR: Vedolizumab (rch) [Word, 966.03 KB]

Attachment: Product Information: Vedolizumab (rch) [PDF, 202.62 KB]

Attachment: Product Information: Vedolizumab (rch) [Word, 77.81 KB]

Attachment: Extract from the Clinical Evaluation Report: Vedolizumab (rch) [PDF, 905.18 KB]

Attachment: Extract from the Clinical Evaluation Report: Vedolizumab (rch) [Word, 1.03 MB]

Device/Product Name

Entyvio / Kynteles

Active ingredients

Vedolizumab (rch)

AusPAR Date

17 November 2014

Published

11 December 2014

Submission Number

PM-2013-01102-1-1

Submission Type

New biological entity

Decision

Approved

This webpage on the TGA website was printed on 12 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/resources/auspar/auspar-vedolizumab-rch

Sub menu

AusPAR: Vedolizumab (rch)

Help us improve the Therapeutic Goods Administration site